RxDoctor Payments Data

Nathan Papadeas, PA

Physician Assistant · Mesa, AZNPI 1255734760

Payments from drug & device makers

$2,343in general payments, 2019–2025

Across 101 payments — averaging $23.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$328
  • AbbVie$311
  • Myriad Genetic Laboratories, Inc.$309
  • Ferring Pharmaceuticals Inc.$196
  • Endo USA, Inc.$158
  • Progenics Pharmaceuticals, Inc.$138
  • plus $902 from 20 others

What the payments were for

  • Food & beverage$2,25896%
  • Education$854%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,343 in reported general payments places this provider in the 80th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$97,199
Medicare patients
411
Services billed
2,312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron93$60,266
GemtesaVibegron89$58,985
XyostedTestosterone Enanthate17$10,348
Methenamine Hippurate125$9,837
Testosterone27$5,908
Tamsulosin Hcl437$5,357
Solifenacin Succinate90$5,122
Dutasteride56$2,289
Alfuzosin Hcl ErAlfuzosin Hcl118$2,283
Testosterone Cypionate50$2,110
Potassium Citrate ErPotassium Citrate18$1,882
Estradiol30$1,775
Finasteride127$1,657
Oxybutynin Chloride ErOxybutynin Chloride94$1,490
Silodosin18$1,446

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$24$58,98589 claims
Antares Pharma, Inc.Xyosted$138$10,34817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →